p27(Kip1) expression in breast carcinomas: An immunohistochemical study on 512 patients with long-term follow-up

Mattia Barbareschi, Harm Van Tinteren, Francesco A. Mauri, Silvio Veronese, Hans Peterse, Patrik Maisonneuve, Orazio Caffo, Monica Scaioli, Claudio Doglioni, Enzo Galligioni, Paolo Dalla Palma, Rob Michalides

Research output: Contribution to journalArticle

Abstract

p27(Kip1) (p27), a cyclin-dependent kinase inhibitor, has an important role in the progression of cells from G1 into S phase of the cell cycle. p27 may act as a tumor suppressor, and several reports suggest that loss of its expression in breast carcinoma is related to tumor progression and poor prognosis. We evaluated p27 immunohistochemical expression in 512 consecutive cases of breast carcinoma with 9 years of median-term follow-up. p27 expression was heterogeneous and frequently less intense than in normal cells. Low p27 expression (

Original languageEnglish
Pages (from-to)236-241
Number of pages6
JournalInternational Journal of Cancer
Volume89
Issue number3
DOIs
Publication statusPublished - 2000

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Barbareschi, M., Van Tinteren, H., Mauri, F. A., Veronese, S., Peterse, H., Maisonneuve, P., Caffo, O., Scaioli, M., Doglioni, C., Galligioni, E., Dalla Palma, P., & Michalides, R. (2000). p27(Kip1) expression in breast carcinomas: An immunohistochemical study on 512 patients with long-term follow-up. International Journal of Cancer, 89(3), 236-241. https://doi.org/10.1002/1097-0215(20000520)89:3<236::AID-IJC5>3.0.CO;2-Z